Key Takeaways:
India’s Sun Pharmaceutical Industries will acquire global healthcare company Organon & Co. for $14.00 per share in an all-cash deal, giving the women's health specialist an enterprise value of $11.75 billion.
"This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives," Dilip Shanghvi, Executive Chairman of Sun Pharma, said in a joint statement. "Organon’s portfolio, capabilities and global reach are highly complementary to our own."
The acquisition values Organon's equity at approximately $3.6 billion based on its outstanding shares, with Sun Pharma assuming Organon's $8.6 billion in debt. For the year ended December 31, 2025, Organon reported $6.2 billion in revenue. Sun Pharma plans to fund the deal through available cash and committed financing from banks including Citigroup, J.P. Morgan, and MUFG Bank.
The move will transform Sun Pharma into a top 25 global pharmaceutical player, establishing it as a top-three company in women's health and a top-10 competitor in the biosimilars market. The combined entity is projected to have revenues of $12.4 billion and will have a presence in 150 countries.
Organon shares (NYSE: OGN) surged 31% to $11.26 on Friday following reports of the impending deal, as noted by The Economic Times. The acquisition price of $14.00 per share represents a significant premium to the stock's recent trading levels. The transaction has been approved by the boards of both companies and now awaits approval from Organon stockholders and regulators.
The deal marks a strategic expansion for Sun Pharma, significantly growing its innovative medicines business and providing a strong entry into the biosimilars space. Organon, which was spun off from Merck in 2021, brings a portfolio of more than 70 products in women’s health and general medicines.
"Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," said Carrie Cox, Executive Chair of Organon.
The acquisition is expected to nearly double Sun Pharma's EBITDA and cash flow, supporting deleveraging from a post-transaction net debt to EBITDA ratio of 2.3x. Financial advisors for Sun Pharma include J.P. Morgan Securities LLC and Jefferies LLC, while Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC advised Organon.
This acquisition solidifies Sun Pharma's position as a major global pharmaceutical force and signals continued consolidation within the industry. The deal's success now hinges on regulatory approvals and the final vote from Organon's shareholders, with an expected closing in early 2027.
This article is for informational purposes only and does not constitute investment advice.
